INT48901

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1994
Last Reported 2010
Negated 2
Speculated 3
Reported most in Abstract
Documents 186
Total Number 189
Disease Relevance 136.33
Pain Relevance 57.87

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IL6) aging (IL6) extracellular region (IL6)
Anatomy Link Frequency
plasma 5
macrophages 4
synovium 4
blood 3
monocytes 3
IL6 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 2673 100.00 Very High Very High Very High
cytokine 1791 100.00 Very High Very High Very High
Inflammatory response 226 100.00 Very High Very High Very High
endometriosis 168 100.00 Very High Very High Very High
metalloproteinase 148 100.00 Very High Very High Very High
bradykinin 47 100.00 Very High Very High Very High
abatacept 338 99.98 Very High Very High Very High
rheumatoid arthritis 1662 99.96 Very High Very High Very High
Hyperalgesia 2 99.92 Very High Very High Very High
Arthritis 1063 99.90 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 3347 100.00 Very High Very High Very High
Cancer 1182 100.00 Very High Very High Very High
Osteoporosis 462 100.00 Very High Very High Very High
Obesity 438 100.00 Very High Very High Very High
Necrosis 252 100.00 Very High Very High Very High
Endometriosis 224 100.00 Very High Very High Very High
Deafness 13 100.00 Very High Very High Very High
Otitis Media With Effusion 184 99.98 Very High Very High Very High
Rheumatoid Arthritis 2091 99.96 Very High Very High Very High
Targeted Disruption 38 99.96 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The observed reduction of IL-6 and/or PGE2 from astrocytes may be involved in the mechanism underlying the beneficial effects of these drugs in AD.
Negative_regulation (reduction) of IL-6 in astrocytes associated with disease
1) Confidence 0.57 Published 1997 Journal Brain Res. Section Abstract Doc Link 9449430 Disease Relevance 0.48 Pain Relevance 0.12
Furthermore, treatment of RA patients with methotrexate or gold therapy results in decreased levels of IL-6 in patients with concomitant improvement in additional measures of disease activity (Madhok et al 1993b; Straub et al 1997).
Negative_regulation (decreased) of IL-6 associated with rheumatoid arthritis, disease and methotrexate
2) Confidence 0.52 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621374 Disease Relevance 1.14 Pain Relevance 0.28
Additional studies analyzing its effects in varied populations of RA patients, as well as greater detail concerning its longer-term tolerability and safety, will help define the ultimate role of tocilizumab and other future inhibitors of IL-6 activity as potential therapies for RA.



Negative_regulation (inhibitors) of IL-6 associated with rheumatoid arthritis
3) Confidence 0.52 Published 2008 Journal Therapeutics and Clinical Risk Management Section Abstract Doc Link PMC2621374 Disease Relevance 0.63 Pain Relevance 0.28
Inhibitors of IL-6 were successful in animal models of autoimmune disease paving the way for subsequent studies in humans.
Negative_regulation (Inhibitors) of IL-6 associated with autoimmune disease
4) Confidence 0.52 Published 2008 Journal Therapeutics and Clinical Risk Management Section Abstract Doc Link PMC2621374 Disease Relevance 0.82 Pain Relevance 0.36
The IL-6 levels were significantly reduced at 3 months and 9 months compared to baseline for FH (P < 0.005) and NFH (P < 0.0001).
Negative_regulation (reduced) of IL-6 associated with hyperlipoproteinemia type ii
5) Confidence 0.50 Published 2007 Journal Immun Ageing Section Body Doc Link PMC1845171 Disease Relevance 0.68 Pain Relevance 0.03
In addition, tenidap reduces circulating levels of IL-6 in RA patients.
Negative_regulation (reduces) of IL-6 associated with rheumatoid arthritis
6) Confidence 0.50 Published 1994 Journal Scand. J. Rheumatol. Suppl. Section Abstract Doc Link 7532319 Disease Relevance 1.13 Pain Relevance 0.64
In the experimental silicosis model, IL-6 activities in the sera and in the culture supernatants of pulmonary fibroblasts were also inhibited by it.
Negative_regulation (inhibited) of IL-6 in fibroblasts associated with occupational lung diseases
7) Confidence 0.50 Published 1996 Journal Mediators Inflamm Section Abstract Doc Link PMC2365809 Disease Relevance 1.21 Pain Relevance 0.45
BEAS-2B cells, pretreated with amiloride before ROFA exposure, showed a partial (approximately 25%) reduction of IL-6.
Spec (partial) Negative_regulation (reduction) of IL-6 in BEAS-2B
8) Confidence 0.48 Published 1999 Journal Toxicol. Appl. Pharmacol. Section Abstract Doc Link 9882597 Disease Relevance 0.16 Pain Relevance 0.69
Dexamethasone was found to be a potent inhibitor of IL6 gene in connective tissue-type cells from the synovium of patients with RA [66].
Negative_regulation (inhibitor) of IL6 gene in synovium associated with dexamethasone and arthritis
9) Confidence 0.48 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2855702 Disease Relevance 0.73 Pain Relevance 0.43
IL6 was also inhibited by SB-203580, a p38 MAPK inhibitor, in IL1B treated broblast-like synoviocytes (FLS) cells [31].
Negative_regulation (inhibited) of IL6
10) Confidence 0.48 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2855702 Disease Relevance 0.79 Pain Relevance 0.44
Tissue levels of IL-1 beta and IL-6 were not affected after the 400mg dose but decreased significantly (44+/-32% and 38+/-13%) after the 800 mg dose.
Neg (not) Negative_regulation (decreased) of IL-6
11) Confidence 0.45 Published 2008 Journal Pain Section Abstract Doc Link 18396374 Disease Relevance 0.98 Pain Relevance 0.80
This study showed the superiority of blocking IL-6 with tocilizumab compared with conventional DMARDs in inhibiting radiographic progression.


Negative_regulation (blocking) of IL-6
12) Confidence 0.45 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727785 Disease Relevance 0.47 Pain Relevance 0.35
However, as well as yielding normalization of CRP and SAA levels, inhibition of IL-6 by tocilizumab makes IL-6-induced fever and general fatigue less prominent.
Negative_regulation (inhibition) of IL-6 associated with fatigue and fever
13) Confidence 0.45 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727785 Disease Relevance 0.92 Pain Relevance 0
Serum interleukin-6 (IL-6) concentration was initially elevated, decreased after the start of adrenergic blockade, and gradually fell to an undetectable level after surgery.
Negative_regulation (decreased) of IL-6
14) Confidence 0.43 Published 1997 Journal Scand. J. Infect. Dis. Section Abstract Doc Link 9571753 Disease Relevance 1.00 Pain Relevance 0.13
Serum interleukin-6 (IL-6) concentration was initially elevated, decreased after the start of adrenergic blockade, and gradually fell to an undetectable level after surgery.
Negative_regulation (decreased) of interleukin-6
15) Confidence 0.43 Published 1997 Journal Scand. J. Infect. Dis. Section Abstract Doc Link 9571753 Disease Relevance 1.01 Pain Relevance 0.13
The study hypothesis is grounded in the assumption that exercising with 75% of the maximum load at a frequency of three times per week for 10 weeks may be sufficient to provide strength gains, and consequently improve functional ability and reduce the plasma levels of IL-6 and TNF-?.
Negative_regulation (reduce) of IL-6 in plasma
16) Confidence 0.42 Published 2010 Journal Trials Section Body Doc Link PMC2919525 Disease Relevance 0.34 Pain Relevance 0.06
Interleukin-1 beta, interleukin-6, and tissue inhibitor of metalloproteinase-1 in the synovial fluid of the temporomandibular joint with respect to cartilage destruction.
Negative_regulation (inhibitor) of interleukin-6 in synovial fluid associated with snapping jaw and metalloproteinase
17) Confidence 0.42 Published 2000 Journal Oral Dis Section Title Doc Link 11355271 Disease Relevance 0.10 Pain Relevance 0.45
Subsequently, IL-6 levels declined and were no longer detectable, while TNF levels increased among ACS patients at all time periods tested when compared with other patients.
Negative_regulation (declined) of IL-6
18) Confidence 0.42 Published 2005 Journal Vascular Health and Risk Management Section Abstract Doc Link PMC1993951 Disease Relevance 0.60 Pain Relevance 0.25
Healthy subjects had almost no response to inhaled dust, but HDM-allergic subjects showed varied responses: DEHPlow house dust increased eosinophil cationic protein, granulocyte-colony┬ľstimulating factor (G-CSF), interleukin (IL)-5, and IL-6, whereas DEHPhigh house dust decreased G-CSF and IL-6.
Negative_regulation (decreased) of IL-6 in granulocyte associated with hypersensitivity
19) Confidence 0.42 Published 2008 Journal Environ Health Perspect Section Abstract Doc Link PMC2592268 Disease Relevance 0.40 Pain Relevance 0
This review has summarized the available evidence from randomized controlled trials of IL-6 inhibition in the treatment for RA.
Negative_regulation (inhibition) of IL-6 associated with rheumatoid arthritis
20) Confidence 0.41 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2990387 Disease Relevance 0.70 Pain Relevance 0.32

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox